Revolution Medicines

102 articles about Revolution Medicines

• Revolution Medicines to Participate in Upcoming Investor Conferences in September 2022

  8/31/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.

• Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

  8/9/2022

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2022, and provided an update on corporate progress.

• Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - July 22, 2022

  7/22/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the closing of an underwritten public offering of 13,225,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.

• Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

  7/20/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.

• Revolution Medicines Announces Commencement of Public Offering of Common Stock - July 19, 2022

  7/19/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that it has commenced an underwritten public offering to sell up to $200 million of shares of its common stock.

• Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

  7/13/2022

  Revolution Medicines, Inc. today announced the appointment of Lorence Kim, M.D., to its board of directors.

• Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

  6/9/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference.

• Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

  4/21/2022

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on Monday, May 9, 2022, after market close.

• Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

  3/9/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the company will make seven oral presentations at the upcoming American Association for Cancer Research Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.

• Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

  3/1/2022

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference.

• Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

  2/28/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

• Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

  2/3/2022

  Revolution Medicines, Inc., a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference.

• Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

  1/11/2022

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today reported progress across its pipeline of targeted therapeutics spanning its RAS(ON) Inhibitor and RAS Companion Inhibitor portfolios.

• Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Revolution Medicines, Inc. today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 40th Annual J.P. Morgan Healthcare Conference.

• Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

  11/24/2021

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference.

• Revolution Medicines Reports Third Quarter 2021 Financial Results and Update on Corporate Progress

  11/10/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

• Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

  11/8/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced that the company will participate in the upcoming Stifel 2021 Virtual Healthcare Conference.

• Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

  11/3/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced that it will report financial results for the third quarter 2021 on November 10, 2021 after market close.

• Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets

  9/30/2021

  Revolution Medicines, Inc. today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference being held on October 7-10, 2021.

• Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development SummitCompany’s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

  9/15/2021

  Revolution Medicines, Inc. today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021.